Capecitabine plus oxaliplatin compared with fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results of the NO16968 randomized controlled phase III trial. J Clin Oncol 2015; 33: 3733-3740.

Published: 29th March 2016

Authors: Schmoll H-J, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E et al. et al.


In this study that included 1886 patients, capecitabine/oxaliplatin improved disease-free survival after seven years (hazard ratio 0.8, 95 per cent confidence interval 0.69 to 0.93, P=0.004) and overall survival: 73 versus 67 per cent, P=0.04.

Pubmed Link

Your comments